Literature DB >> 17211768

[Guidelines for health-economic evaluations in Austria].

Evelyn Walter1, Susanne Zehetmayr.   

Abstract

BACKGROUND: The evaluative health economics is a recent field of research in health economics. Cost-effectiveness decisions play an increasing role, particularly for policy-makers to find systematic decisions under uncertainty. The task is all the more important as the use of innovative health technologies for diagnosis, prevention and treatment is rapidly expanding and thus leads to financial restrictions in health care. Hence, decision making has to be supported by systematically implementing analytical tools.
METHODS: When it comes to interpret the results of health-economic evaluations in a valid way it is necessary that state-of-the-art methodology is carried out in a transparent way. It is in this vein that guidelines were developed for Austria. On the one hand, they should set standards but, on the other hand, they should not restrict methodical progress guided by freedom of scientific research in health economics.
CONCLUSIONS: Setting guidelines of health-economic evaluations is an important breakthrough in Austria.

Mesh:

Year:  2006        PMID: 17211768     DOI: 10.1007/s10354-006-0360-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  9 in total

1.  [Theoretical implications of health economic evaluations in an Austrian context].

Authors:  Evelyn Walter; Susanne Zehetmayr
Journal:  Wien Med Wochenschr       Date:  2006-12

Review 2.  Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments.

Authors:  Neily Zakiyah; Maarten J Postma; Philip N Baker; Antoinette D I van Asselt
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

3.  Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.

Authors:  B Jahn; U Rochau; C Kurzthaler; M Hubalek; R Miksad; G Sroczynski; M Paulden; M Kluibenschädl; M Krahn; U Siebert
Journal:  Springerplus       Date:  2015-12-01

Review 4.  Costing evidence for health care decision-making in Austria: A systematic review.

Authors:  Susanne Mayer; Noemi Kiss; Agata Łaszewska; Judit Simon
Journal:  PLoS One       Date:  2017-08-14       Impact factor: 3.240

5.  Improving patient flow of people with rheumatoid arthritis has the potential to simultaneously improve health outcomes and reduce direct costs.

Authors:  R Puchner; R Hochreiter; H Pieringer; A Vavrovsky
Journal:  BMC Musculoskelet Disord       Date:  2017-01-07       Impact factor: 2.362

6.  Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online.

Authors:  Beate Jahn; Ursula Rochau; Christina Kurzthaler; Michael Hubalek; Rebecca Miksad; Gaby Sroczynski; Mike Paulden; Marvin Bundo; David Stenehjem; Diana Brixner; Murray Krahn; Uwe Siebert
Journal:  BMC Cancer       Date:  2017-10-16       Impact factor: 4.430

7.  The societal costs of chronic pain and its determinants: The case of Austria.

Authors:  Susanne Mayer; Jonah Spickschen; K Viktoria Stein; Richard Crevenna; Thomas E Dorner; Judit Simon
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

Review 8.  Assessing the Effect of Including Social Costs in Economic Evaluations of Diabetes-Related Interventions: A Systematic Review.

Authors:  Beatriz Rodriguez-Sanchez; Isaac Aranda-Reneo; Juan Oliva-Moreno; Julio Lopez-Bastida
Journal:  Clinicoecon Outcomes Res       Date:  2021-04-29

9.  Rival perspectives in health technology assessment and other economic evaluations for investing in global and national health. Who decides? Who pays?

Authors:  Anthony Culyer; Kalipso Chalkidou; Yot Teerawattananon; Benjarin Santatiwongchai
Journal:  F1000Res       Date:  2018-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.